Repare Therapeutics Inc. - RPTX STOCK NEWS

DCx's strategy focuses on developing MM-ADCs that target both intracellular and cell-surface targets to improve efficacy, prolong activity, and enhance tolerability compared to traditional ADCs that use broadly chemotoxic payloads.

Repare Therapeutics (RPTX) announced the acceptance of six abstracts for presentation at the AACR Annual Meeting 2025 in Chicago. The presentations include two mini-oral sessions and four poster presentations focusing on various oncology research developments.

The mini-oral presentations will feature the Phase I MYTHIC study results on the combination of PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in ovarian and endometrial cancers, and research on PLK4 inhibitor RP-1664 in neuroblastoma models.

The poster presentations will cover topics including:

• Dual mechanism of PLK4 inhibition sensitivity
• RP-1664's effects in TRIM37-high xenograft models
• Pan-cancer analysis of TRIM37 copy-number
• CCNE1 amplification targeting in gastric cancer

Repare Therapeutics (NASDAQ: RPTX) announced key leadership changes effective April 11, 2025. Steve Forte, current Executive Vice President and CFO, has been appointed as President, CEO, and Board Director, while maintaining his CFO role. Lloyd M. Segal has resigned from his positions as President, CEO, and Board Director to pursue other opportunities.

Forte, who joined Repare in 2019, brings over 20 years of finance and biotech leadership experience. He previously served as CFO at Clementia Pharmaceuticals, which was acquired by Ipsen for $1.3 billion. Additionally, Sandra Alves has been promoted from VP and Corporate Controller to Chief Accounting Officer.

The clinical-stage precision oncology company is currently advancing three Phase 1 trials: the MYTHIC trial (lunresertib with Debio 0123) expecting completion in Q2 2025, the POLAR trial (RP-3467) with data expected in Q3 2025, and the LIONS trial (RP-1664 with olaparib) with initial data expected in Q4 2025. The company is also exploring strategic alternatives and partnerships for lunresertib and camonsertib.

Repare Therapeutics (Nasdaq: RPTX) has announced the granting of stock options to two new employees through its 2024 Inducement Plan. The Compensation Committee approved two separate grants:

1. A stock option granted on November 5, 2024, with an exercise price of $3.59 per share

2. A stock option granted on March 5, 2025, with an exercise price of $1.17 per share

The total aggregate amounts to 22,200 common shares. Both options have ten-year terms and will vest over four years, with 25% vesting after one year and the remainder vesting in monthly installments. These grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).

Repare Therapeutics (RPTX) has announced significant business restructuring and clinical updates for Q4 and full year 2024. The company is implementing a 75% workforce reduction while maintaining $152.8 million in cash reserves, extending runway to late-2027. Three key clinical trials are progressing with expected readouts in 2025:

- POLAR trial (RP-3467 Polθ inhibitor) data expected Q3 2025
- LIONS trial (RP-1664 PLK4 inhibitor) readout expected Q4 2025
- MYTHIC trial evaluating lunresertib combination therapy

Financial highlights include revenue from collaborations of $53.5 million for 2024, reduced R&D expenses of $115.9 million (down from $133.6 million in 2023), and a net loss of $84.7 million ($2.00 per share) for 2024.

Repare Therapeutics (RPTX) announced a strategic portfolio re-prioritization focusing on two Phase 1 clinical programs: RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor). The company will seek partnerships for its Lunre+Camo program before pivotal development.

The restructuring includes cost and headcount reductions, extending cash runway to mid-2027. With approximately $153 million in cash at 2024-end, Repare will concentrate on achieving near-term milestones, with initial clinical readouts expected in Q3 2025.

Key upcoming milestones include: RP-1664's Phase 1/2 expansion trial initiation in pediatric neuroblastoma (Q3 2025) and LIONS trial data (Q4 2025); RP-3467's POLAR trial data in Q3 2025. The company will discontinue development of lunresertib and camonsertib in other studies unless securing partnership agreements.

Repare Therapeutics (RPTX) reported positive results from its MYTHIC Phase 1 gynecologic expansion trial combining lunresertib and camonsertib (Lunre+Camo). The trial showed a 25.9% overall response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer. Nearly half of patients maintained progression-free survival at 24 weeks.

The study included heavily pretreated patients, with many receiving the treatment as fourth line or beyond. In endometrial cancer patients, 100% had prior platinum therapy and 77.8% received immune checkpoint inhibitors. For ovarian cancer patients, all were platinum-resistant or ineligible, with 45.8% having received prior PARP inhibitors.

The company plans to initiate a registrational Phase 3 trial for endometrial cancer in second half of 2025.

Repare Therapeutics (Nasdaq: RPTX) announced a webcast presentation of data from its Phase 1 MYTHIC clinical trial on December 12, 2024. The trial evaluates the combination of lunresertib and camonsertib at the recommended Phase 2 dose in patients with platinum-resistant ovarian and endometrial cancers with specific genetic markers (CCNE1 amplification or FBXW7 or PPP2R1A mutations).

The presentation will feature Dr. Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center, alongside Repare's executive management team. The event will be accessible via conference call and live video webcast through the company's investor relations website.

Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly demonstrating prolonged progression-free survival in ATM-mutated non-small cell lung cancer patients. Recent Phase 1 results combining camonsertib with radiotherapy showed complete responses in patients with ATM-altered tumors. CTEP will focus on combination studies involving camonsertib with radiation therapy and translational studies for biomarker identification.